Supernus Pharmaceuticals SUPN Total costs & expenses
Total costs & expenses at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CostsAndExpenses.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's total costs & expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's total costs & expenses?
- Supernus Pharmaceuticals (SUPN) reported total costs & expenses of $216.04M in Q1 2026.
- How has Supernus Pharmaceuticals's total costs & expenses changed year-over-year?
- Supernus Pharmaceuticals's total costs & expenses increased by 35.0% year-over-year, from $160.08M to $216.04M.
- What is the long-term trend for Supernus Pharmaceuticals's total costs & expenses?
- Over 4 years (2021 to 2025), Supernus Pharmaceuticals's total costs & expenses has grown at a 12.2% compound annual growth rate (CAGR), from $493.75M to $781.24M.
- What does total costs & expenses mean?
- This metric aggregates all operating and non-operating costs incurred by the company to generate revenue, including cost of goods sold, research and development, and selling, general, and administrative expenses. It provides a comprehensive view of the total resource consumption required to sustain business operations. Monitoring this figure is essential for evaluating the company's overall cost structure and operational efficiency.